Navigation Links
Mesothelin engineered on virus-like particles provides treatment clues for pancreatic cancer
Date:2/14/2008

New understanding of a protein that spurs the growth of pancreatic cancer could lead to a new vaccine against the deadly disease, said researchers at Baylor College of Medicine in Houston in a report appearing in the current edition of the journal Molecular Cancer Therapeutics.

The protein called mesothelin appears to play an important role in promoting pancreatic cancer growth, said the senior author Dr. Qizhi (Cathy) Yao, professor of surgery vascular surgery at BCM. She, along with co-lead authors Dr. Min Li, assistant professor of surgery, and research associate Dr. Uddalak Bharadwaj carried out the studies of the protein that is found on the tumor cells surface.

Mesothelin is found in other cancers for several years, said Yao, also a researcher in the Dan L. Duncan Cancer Center at BCM. However, we didnt know the role it played in pancreatic cancer: until she and her colleagues reported in this article. In fact, they found very high levels of mesothelin in 18 of 21 samples of patients pancreatic tissues compared to amounts found in nearby normal tissues. In studies of this protein in the lab, pancreatic cancer cell lines that produced high levels of mesothelin grew faster and spread more than those in which mesothelin levels were lower.

Pancreatic cancer cells grew and spread faster in mice whose tumors expressed high levels of mesothelin than in those whose cancer did not, said the researchers, who conducted the studies in an immune deficient mouse.

We saw this molecule as very significant in the life of the tumor cells, Yao said. Our next step is to identify whether this would be a good active immunotherapy target.

Making a treatment vaccine of virus-like particles (VLPs) that contained mesothelin, researchers injected mice having pancreatic cancer with this vaccine three times. Virus-like particles have the unique property of inducing protective immune responses but they lack the infectious capacities of the original virus.

Tumor growth in the immunized mice slowed and in some cases the tumor disappeared. The average life span for the mice not treated was four weeks. The immunized mice survived five weeks longer than those not treated.

Researchers found that the immunization works by suppressing production of key immune system cells that suppress the bodys ability to fight the tumor. The researchers said pancreatic cancers produce these cells, called T regulatory cells, as a protective measure.

If we are able to see the same results in humans, this would allow us to incorporate a combination therapy to treat the tumor, Yao said. Treatment with a single drug is not effective.

Yao and her colleagues are seeking U.S. Food and Drug Administration approval to begin studies using their vaccination on people suffering from pancreatic cancer.


'/>"/>

Contact: Graciela Gutierrez
ggutierr@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Related biology news :

1. MIT works toward engineered blood vessels
2. Engineered weathering process could mitigate global warming
3. Genetically engineered corn may harm stream ecosystems
4. Study shows genetically engineered corn could affect aquatic ecosystems
5. Engineered eggshells to help make hydrogen fuel
6. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
7. A step toward tissue-engineered heart structures for children
8. Tiny dust particles from Asian deserts common over western United States
9. MIT sculpts 3-D particles with light
10. MIT: Remote-control nanoparticles deliver drugs directly into tumors
11. Worldwide atmospheric measurements will determine the role of atmospheric fine particles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... MONTREAL , Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... as President and CEO and Fabrice Orecchioni, the company,s COO, has ... as COO over the past four years, Fabrice has overseen the ... Sarnia and the management of the Mitsui JV.  Fabrice ... for the proposed China JV. ...
(Date:2/20/2017)... , Feb. 20, 2017 This report analyzes the ... following Product Types: Xylanase, Amylase, Cellulase, and Others. The report ... , Japan , Europe ... America , and Rest of World. ... estimates and forecasts are provided for the period 2015 through ...
(Date:2/20/2017)... ... February 20, 2017 , ... Cancer ... “Crosswalk Insight: Oncology™” (Crosswalk), a unique precision medicine knowledge visualization and decision support ... accessed through Inspirata’s diagnostic cockpit and is downloadable as an app for any ...
(Date:2/20/2017)... Philadelphia, PA (PRWEB) , ... ... ... technologies to improve therapeutic success among radiotherapy patients, prevent chest wall collapses ... for femur fracture alignments will receive a total of $600,000 in funding ...
Breaking Biology Technology: